Primary Peritoneal Carcinoma Recruiting Phase 1 / 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02726997Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Treatment